Brivoligide - Adynxx

Drug Profile

Brivoligide - Adynxx

Alternative Names: AYX-1

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adynxx
  • Class Analgesics; Oligonucleotides
  • Mechanism of Action Early growth response protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pain; Postoperative pain

Most Recent Events

  • 04 Oct 2017 Adynxx comples enrolment in a phase II trial for Postoperative and Chronic pain (Prevention) in USA (Intrathecal) (NCT02807428)
  • 12 May 2017 Brivoligide is still in phase II trials for Postoperative pain and Chronic pain (Prevention) in USA (Intrathecal) (Adynxx website, May 2017)
  • 01 Feb 2017 Adynxx initiates a phase II trial for Postoperative and Chronic pain (Prevention) in USA (Intrathecal) (NCT02807428)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top